Placement Pending
Candid Therapeutics placement
US$505m raised
Announced 2 Mar 2026
Advisers
Candid Therapeutics
Issuer
- Legal adviser
Lead managers
- Legal adviser
- Placement agent
- TD Securities (as TD Cowen)
- Issuer
- Candid Therapeutics
- Issuer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Drug Development
Similar deals
- ADARx Pharmaceuticals IPO Sep 2026 · US$446m · Biotech
- Amylyx Pharmaceuticals equity raising Aug 2026 · US$575m · Biotech
- Kailera Therapeutics IPO Apr 2026 · US$625m · Biotech
- Generate Biomedicines IPO Feb 2026 · US$400m · Biotech
- Kardigan IPO Jun 2026 · US$400m · Biotech
Sources
- Mar 2026 Latham Advises on Financing in Connection with Rallybio Candid Therapeutics Merger lw.com
- 2 Mar 2026 Press release (EX-99.1, exhibit), Rallybio Corporation and Candid Therapeutics Announce Merger Agreement sec.gov
- 2 Mar 2026 Candid Therapeutics Announces Merger With Rallybio Corporation, Concurrent Private Financing of $505+ Million cooley.com



